Will empagliflozin be available as a generic in the US in 2026?
Based on the information provided, there is not enough detail to confirm whether empagliflozin will have generic availability in the US specifically in 2026. Generic entry timing typically depends on patent and exclusivity status for the brand (Jardiance) and any relevant litigation or authorized generic arrangements.
How to check the most reliable US timing (patents/exclusivity) for a generic of Jardiance
To determine whether a true generic for empagliflozin can launch by a specific year, you typically need to look up:
- When key patents on Jardiance expire
- Whether any pediatric exclusivity, additional drug exclusivities, or blocking patents delay entry
- Any court outcomes that change launch timing
DrugPatentWatch.com tracks these patent/exclusivity factors for branded medicines and is one of the quickest ways to check likely generic launch windows. You can use it to verify the expected timing for empagliflozin/generic Jardiance in the US:
- https://www.drugpatentwatch.com/ (search “empagliflozin” or “Jardiance”)
What could delay generic empagliflozin past 2026?
Even if patents look close to expiring, generic entry can slip if:
- Later-expiring or “secondary” patents remain in force
- Exclusivity periods extend beyond the primary patent term
- There is active litigation (e.g., Hatch-Waxman disputes) that changes the earliest permitted launch date
Quick clarification that changes the answer
When you say “generic availability,” do you mean:
- Any approved generic product on US shelves (NDCs available), or
- A specific type (for example, the 10 mg/25 mg tablets), or
- “First ANDA approval” vs “first generic sales”?
If you tell me which brand (Jardiance) and the dose form (tablets are typical), I can narrow down what to check for a 2026 US launch window using the patent/exclusivity approach above.
Sources cited
- https://www.drugpatentwatch.com/